Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relief Therapeutics Hldg Ag (OP: RLFTF )

1.450 UNCHANGED
Streaming Delayed Price Updated: 12:02 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,334
Open 1.310
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.450
Today's Range 1.310 - 1.450
52wk Range 0.0137 - 4.750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
From Eton Pharmaceuticals
Via GlobeNewswire
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
Via ACCESSWIRE

Performance

YTD
-40.33%
-40.33%
1 Month
-11.59%
-11.59%
3 Month
-26.77%
-26.77%
6 Month
-34.09%
-34.09%
1 Year
+7412.95%
+7412.95%

More News

Read More
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Via ACCESSWIRE
Relief Therapeutics Announces CEO Transition
Via ACCESSWIRE
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Via ACCESSWIRE
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
Via ACCESSWIRE
Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
Via ACCESSWIRE
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
Via ACCESSWIRE
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
Via ACCESSWIRE
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
Via ACCESSWIRE
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
Via ACCESSWIRE
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Via ACCESSWIRE
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Via ACCESSWIRE
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Relief Therapeutics Announces Executive Leadership Team Change
Via ACCESSWIRE
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Via ACCESSWIRE
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Via ACCESSWIRE
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
Via ACCESSWIRE
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA
Via ACCESSWIRE
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars
Via ACCESSWIRE
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
Via ACCESSWIRE
Relief Therapeutics Provides an Update on its Financing Strategy
Via ACCESSWIRE
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.